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The mechanisms controlling mammalian organ size have long been a source of fascination for biologists. These controls are needed to
both ensure the integrity of the body plan and to restrict inappropriate proliferation that could lead to cancer. Regulation of liver size
is of particular interest inasmuch as this organ maintains the capacity for regeneration throughout life, and is able to regain precisely its
original mass after partial surgical resection. Recent studies using genetically engineered mouse strains have shed new light on this
problem; the Hippo signalling pathway, first elucidated as a regulator of organ size in Drosophila, has been identified as dominant
determinant of liver growth. Defects in this pathway in mouse liver lead to sustained liver overgrowth and the eventual development
of both major types of liver cancer, hepatocellular carcinoma and cholangiocarcinoma. In this review, we discuss the role of Hippo
signalling in liver biology and the contribution of this pathway to liver cancer in humans.
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Liver cancer is the fifth most common cancer worldwide and the
third leading cause of cancer death (Farazi and DePinho, 2006).
The two most common primary liver cancers, hepatocellular
carcinoma (HCC) and cholangiocarcinoma (CC) exhibit distinct
histological and molecular profiles. The conventional view has
been that HCC and CC arise from hepatocytes and bile duct cells
(cholangiocytes), respectively, however the existence of a subset of
liver tumours showing mixed HCC/CC histology has suggested an
origin from a bipotential progenitor cell (Zhang et al, 2008). In
terms of risk factors, a common shared theme is the role of chronic
tissue damage, viral hepatitis and inflammation, suggesting
an important role for repeated cycles of cell injury, death
and regeneration in disease predisposition. Both of these tumour
types carry a poor prognosis with potentially curative surgery
only possible in the subset of patients diagnosed with early disease.
Some responses are seen with conventional and targeted chemo-
therapies, however, the impact on overall survival is modest
(Villanueva et al, 2010). Therefore, the elucidation of the molecular
pathogenesis of HCC and CC is needed to improve therapeutic
approaches for these diseases.
A series of recent studies have demonstrated that the Mst1,
Mst2, Sav1 (also known as WW45), and Yap genes are important
for growth control and tumourigenesis in the liver. Notably, each
of these genes is orthologous to a member of the Drosophila Hippo
tumour suppressor pathway, a gene network that seems to monitor
cell–cell contact and cell polarity, and thereby restrict organ
overgrowth (reviewed in Reddy and Irvine, 2008). Correspond-
ingly, the pathway in mammals is revealed as an evolutionarily
conserved mechanism for both organ size control and tumour
suppression. Not surprisingly however, the expansion of these
genes in mammals is also accompanied by a tissue-specific
diversification of their functions and of the architecture and
regulation of the pathway. In this study, we review distinct aspects
of Hippo signalling operative in the liver, discuss the impact of this
pathway on proliferative control in different hepatic cell lineages,
and evaluate the relevance of defective Hippo signalling to human
liver cancer.
Mst1/2 KINASES AND THE HIPPO PATHWAY
The Mst1/2 kinases are cytosolic Ste20-related kinases activated by
autophosphorylation (Creasy et al, 1996). Designated class II GC
kinases, Mst1 and Mst2, share 76% sequence identity and contain
an N-terminal catalytic domain, followed successively by an
autoinhibitory segment and a coiled-coil SARAH domain that
mediates hetero- and homo-dimerisation. The SARAH domain is
present in a small number of additional mammalian proteins,
including Sav1 and the Rassf/Nore family (Hwang et al, 2007;
Avruch et al, 2009), each of which are non-catalytic adaptors that
have been functionally linked to Mst1/Mst2 (see below). Over-
expression of either Mst1 or Mst2 induces apoptosis in many
transformed cell lines and are themselves activated under a variety
of apoptotic conditions (Graves et al, 1998).
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www.bjcancer.comThe Hippo pathway emerged from Drosophila screens for
genes whose loss results in organ overgrowth. The first element
identified was the Lats kinase, (Xu et al, 1995) and evidence for a
pathway was provided by the elucidation of Salvador (Tapon et al,
2002), which encodes a non-catalytic protein that binds directly to
Lats and has a similar LOF phenotype. The Mst1/Mst2 orthologous
kinase Hippo, identified the following year as a growth suppressor,
was shown to bind Salvador and phosphorylate Lats (reviewed
recently by Reddy and Irvine, 2008). Overgrowth in this pathway
reflects both increased proliferation and a failure of developmental
apoptosis. Several other genes giving phenotypes similar to Hippo
were identified and found to interact genetically and biochemi-
cally. The core of the pathway involves a kinase cascade in which
Hippo phosphorylates the Lats/Warts kinase, which in turn
multiply phosphorylates Yorkie/Yap, a transcriptional co-activator
that controls several classes of transcription factors, including
Scalloped (TEAD domain proteins), homothorax and SMADs
(Oh and Irvine, 2010; Figure 1A). The scaffold protein Salvador/
shar-pei (the Sav1 orthologue), which binds both Hippo and Lats/
Warts, links the pathway to upstream signals. The noncatalytic
protein MATS (MOBKL1A/B) is a Hippo substrate that once
phosphorylated, binds to and promotes Lats autophosphorylation
and activation (Wei et al, 2007; Praskova et al, 2008). Genetic
studies show that elimination of Yorkie reverses the loss-of-
function phenotype of all the other genes, indicating that the
primary function of the pathway is the inhibition of Yorkie/Yap
(Huang et al, 2005). One crucial mechanism of Yorkie inhibition is
through Lats/Warts-catalysed phosphorylation, followed by 14-3-3
binding and nuclear exit (Huang et al, 2005; Ren et al, 2010). The
pathway components and their arrangement upstream of Hippo is
less well defined; among the positive regulators are submembrane
actin-associated FERM domain proteins, such as Merlin, whose
human orthologue is the NF2 tumour suppressor, and an atypical
cadherin called Fat (reviewed in Reddy and Irvine, 2008). Thus,
although the wiring between the cell surface and Hippo is unclear,
cell–cell contact is likely to be an important activating stimulus
(Zhao et al, 2007).
In addition to Mst1/2, Sav1 and Yap, the other core components
of the ‘Hippo pathway’ are conserved in mammals (Warts¼Lats1
and 2; MATS¼Mobkl1a and b) and each can rescue the
Drosophila LOF phenotypes. Initial studies in mammalian cell
culture and in vitro indicated that the regulation of the pathway in
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Figure 1 Hippo pathway circuitry in Drosophila and in the mammalian liver. (A) Model of Drosophila Hippo signaling. Signaling may be initiated in response
to the atypical cadherin Fat receptor activation through Ds binding. Signals are transduced through the FERM domain-containing cytoskeleton-associated
protein, Merlin (Mer) and Expanded (Ex), and by Kibra, a protein that interacts with Mer and Ex. The Hippo kinase interacts with and phosphorylates the
scaffold protein Sav promoting Hippo-mediated phosphorylation of the adaptor Mats and the Wts kinase. Wts is thereby activated and phosphorylates the
transcriptional coactivator Yki. Phosphorylation of Yki induces its cytoplasmic retention through 14-3-3 binding. In the absence of Hippo pathway activation,
Yki is mainly located in the nucleus, wherein it binds and activates various DNA biding transcription factors including Sd, Htx and Tsh to induce expression of
genes implicated in cell growth and survival. B and C components of the Hippo pathway are highly conserved in mammals, wherein they have a critical role
in proliferative control in the liver (mammalian orthologues are indicated with the same colour scheme as the corresponding Drosophila proteins). Although
the circuitry is incompletely defined, it seems that two distinct models either in the oval cells or in hepatocytes can be proposed based on recent studies. In
both cell types, inhibition of the Yki orthologue, Yap, is thought to be a critical output of the pathway. Defects upstream of Yap result in nuclear retention
of Yap, which functions in association with DNA-binding transcription factors, for example, the TEAD domain transcription factors (orthologues of Sd) to
regulate the expression of genes that control cell growth and survival. (B) In hepatocytes, Mst1/2 are required to phosphorylate Mob1. By analogy
to Drosophila, phospho-Mob1 is likely to facilitate activation of an intermediary kinase, which phosphorylates Yap, resulting in both cytoplasmic retention by
14-3-3 binding, as well as cytoplasmic degradation after ubiquitinylation. Lats1/2 activity are unchanged by Mst1/2 inactivation suggesting the existence of a
yet to be defined Mst1/2-regulated Yap kinase. The majority of the catalytically active Mst1/2 in the liver is in a truncated form that lacks the autoregulatory
carboxy-terminus. The upstream activators of Mst1/2 are not defined, although Rassf family proteins, could link Mst1/2 to extracellular signals facilitating
activation before the proteolytic cleavage. Sav1 does not seem to have a role in Yap regulation in hepatocytes. (C) In oval cells, Sav1 controls total Yap
protein levels and levels in the nucleus through yet to be defined mechanisms. The relationship of Sav1 to the Mst1/2 activation state and the
phosphorylation of Yap is not clear, although the Mst1/2-controlled phosphorylation of Yap-Ser127 is unaffected by Sav1 inactivation. Mst1/2 have not been
studied specifically in oval cells, however, the increase in oval cells following Mst1/2 inactivation indicate an important regulatory role for these kinases in oval
cells. The components upstream of these pathways are incompletely defined, although cell–cell contact is likely to be an important stimulus.
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combinations of Mst1/2, Lats1/2 and Sav1 results in Yap
phosphorylation (at Ser127) and nuclear exit, whereas depletion
of Lats1/2 in some cancer cell lines inhibits Yap phosphorylation.
In vitro, Mst2 can phosphorylate purified Lats1/2, and the latter
directly phosphorylates Yap (Ser127) (reviewed in Oh and Irvine,
2010). As regards upstream regulation, mouse embryonic fibro-
blasts (MEFs) on reaching confluence exhibit increased Yap
(Ser127) phosphorylation and reduced nuclear abundance, sug-
gesting that cell–cell contact activates the pathway (Zhao et al,
2007). The importance of Yap phosphorylation and nuclear exit to
contact-induced arrest of proliferation is shown by the ability of a
non-phosphorylatable Yap mutant to bypass contact inhibition.
Notably, MEFs deficient in either NF2/Merlin (Curto and
McClatchey, 2008) or Lats2 (McPherson et al, 2004) also lack
normal contact inhibition. Although these observations suggested
the operation in mammalian cells of a pathway identical to that in
Drosophila, recent studies demonstrate that the pathway upstream
of Yap as well as the regulation and functions of Mst1 and 2 are
each more diverse and tissue specific than anticipated from genetic
analysis of the developing Drosophila eye (see below).
OVERVIEW OF GROWTH CONTROL IN THE LIVER
Growth control in the liver has a number of unusual features
compared with that in other organs. Adult liver cells are largely
quiescent, dividing approximately once/year; nevertheless, differ-
entiated adult hepatocytes, rather than multipotent stem cells, are
the source for tissue replenishment of cell turnover in the
undamaged liver (Ponder, 1996). The liver is also characterised
by a remarkable regenerative capacity (reviewed in Michalopoulos,
2007). In response to removal of up to 70% of liver tissue, liver
mass is restored through cell cycle entry of remaining adult
hepatocytes and cholangiocytes (bile duct cells; Figure 2, right
hand side). If however hepatocyte proliferation is suppressed (e.g.,
in response to hepatotoxins), facultative liver stem cells (oval
cells), a very minor compartment in the normal liver, expand and
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Figure 2 Model for the role of the Hippo pathway during liver regeneration and tumorigenesis. The normal adult liver is mainly composed of two
parenchymal cell types, the hepatocytes and the cholangioctyes that surround the bile ducts. During embryogenesis (not shown), a common progenitor cell
gives rise to these both of these cell types. In the adult, the liver is largely quiescent. The gradual replacement of cells during normal physiologic turnover is
accomplished by the proliferation of the differentiated liver cells. Similarly, in response to various forms of liver injury or to partial hepatectomy, the liver mass
is restored through cell cycle entry of remaining parenchymal cells. In contrast, when parenchymal cells are unable to proliferate (e.g., in responset o
hepatocyte toxins), rare cells associated with the bile ducts known as oval cells expand and then differentiate to restore liver mass. The Mst1/2 kinases seem
to control hepatocyte quiescence by the inhibition of Yap activity. This inhibition may be periodically relieved during normal homostatic turnover, as well as
in response partial hepatectomy. The quiescence of oval cells seem to be controlled both by Mst1/2 and Sav1, and again, Yap is a candidate downstream
target of the pathway. Sustained defects in Mst1/2 result in hepatocyte and oval cell proliferation and the development of HCC and tumors of mixed HCC
and CC histology. Sav1 defects produce comparable phenotypes except that no hepatocyte proliferation is observed.
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to restore liver volume (Figure 2, left hand side). The transcriptional
programme of post-hepatectomy hepatocyte proliferation differs
strongly from that of injury-related, oval cell-mediated regeneration
(Otu et al,2 0 0 7 ) ,t h el a t t e rr e s e m b l i n gm o r ec l o s e l yt h a to f
proliferating fetal hepatoblasts (Bird et al, 2008; Si-Tayeb et al, 2010).
Although numerous models of HCC have been described, no
master regulators of either hepatocyte or oval cell quiescence had
been identified until recently. As regards oval cells, selective
expansion of these cells is observed in mice that overexpress
TWEAK (Jakubowski et al, 2005), a ligand for Fn14, a member of
the TNF receptor family. Moreover, antibody-mediated blockade
of this pathway suppresses oval cell expansion in a liver injury
model. Hence, Tweak signalling can overcome oval cell quiescence
and is required for sustained proliferation of these cells. Never-
theless, TWEAK and Fn14 seems to be constitutively expressed
(Burkly et al, 2007), so that additional mechanisms must restrain
oval cell expansion as well as maintain hepatocyte quiescence.
THE Mst1/2-YAP1 MODULE IN THE REGULATION
OF QUIESCENCE AND PROLIFERATION IN LIVER
The first indication that Yap is important in proliferative control in
the liver came from studies of p53 null primary fetal liver cells
(hepatoblasts) engineered to overexpress the c-Myc oncogene
(Zender et al, 2006). When implanted into mouse liver, these cells
developed into HCC’s that showed recurrent amplification of the
chromosomal locus harbouring Yap. Knockdown of Yap in HCC-
derived cell lines attenuated tumourigenicity, whereas combined
Yap and c-Myc overexpression accelerated HCC development,
providing direct evidence that Yap functions as an oncogene in
the liver. Extension and striking confirmation of this conclusion
was provided by the generation of transgenic mice engineered
to overexpress Yap under a doxycycline-inducible promoter
(Camargo et al, 2007; Dong et al, 2007). In this study, Yap expres-
sion was induced in adult mice either ubiquitously or specifically
in the liver, in both cases leading to immediate and pronounced
liver overgrowth, associated with marked hepatocyte proliferation
and a resistance to apoptosis induced by administration of anti-
FAS antibody. Although liver mass increased five-fold, removal of
doxycycline after 8 weeks resulted in a reversion to normal size
and architecture within 2 weeks. If, however, expression of the Yap
transgene was sustained, multifocal HCC developed within several
months (Dong et al, 2007; Table 1). Hence, Yap expression
overrides hepatocyte quiescence and overall liver size control, and
(as with Drosophila Yorkie) desensitises liver cells to apoptosis.
Yap overexpression also led to aberrant proliferation in the
intestinal epithelium, pancreas and skin, although neither gross
organ enlargement or tumours were reported in these organs
(Camargo et al, 2007).
Recent studies by our group and others using mouse knockouts
of the Mst1/Mst2 kinases (Zhou et al, 2009; Lu et al, 2010; Song
et al, 2010) and the Sav1 scaffold (Le et al, 2010; Lu et al, 2010)
have uncovered critical roles for these putative upstream elements
of the Hippo pathway in proliferation control in the liver (Table 1).
Mst1 and Mst2 single knockout mice are viable and do not exhibit
organ overgrowth or tumour development. Mst1
 / Mst2
 / 
double-knockout mice exhibit early embryonic lethality (Oh
et al, 2009; Zhou et al, 2009), whereas both Mst1
 / Mst2
þ/  and
Mst1
þ/ Mst2
 /  mice are viable and fertile. Notably, however, the
mice born with only a single allele of Mst1 or Mst2 develop
spontaneous liver tumours associated with loss of the remaining
wild-type Mst1 or Mst2 allele in the tumours (Zhou et al, 2009).
The spontaneously arising tumours were all HCCs, although
examination of a large cohort of mice revealed that B10% had
elements of mixed HCC/CC histopathology. At euthanisation,
tumours were not observed in other organs of these mice. These
results establish that Mst1 and Mst2, in a redundant manner,
function as potent tumour suppressors in liver.
The use of the conditional alleles and the albumin (Alb)–Cre
strain enabled study of liver specific homozygous Mst1/Mst2
inactivation (Zhou et al, 2009; Lu et al, 2010; Song et al, 2010).
Compound Alb–Cre, Mst1/Mst2 mutant mice show marked liver
enlargement at 4–5 weeks age and require euthanisation by 4–5
months because of multiple large liver tumours. The precancerous
livers of these mice exhibit overproliferation of hepatocytes as well
as a marked expansion of the oval cell compartment. The liver
tumours show features of both HCC and mixed HCC/CC, with
HCC comprising the larger proportion of the tumour area.
Inasmuch as oval cells are bipotential liver progenitors, the
frequent occurrence of mixed tumour histopathology is probably
attributable to the malignant transformation of these cells resulting
in tumour cells with dual differentiation programs.
Acute Mst1/Mst2 deletion in the adult liver, achieved either by
intravenous injection of adenovirus expressing Cre recombinase
(Zhou et al, 2009), or by tamoxifen induction of MMTV–CreERT
or CAAGS–CreERT (Lu et al, 2010; Song et al, 2010) produced an
intermediate tumour phenotype consisting of both HCC and mixed
HCC/CC histology. Remarkably, acute Mst1/Mst2 deletion caused
a doubling in liver mass associated with marked proliferation
of hepatocytes, a substantial expansion of oval cell, resistance to
FAS-induced apoptosis, and rapid development of liver cancer
(Zhou et al, 2009; Lu et al, 2010). Comparing the various models, it
seems that the timing and/or mechanism of Mst1/Mst2 inactiva-
tion influences the ensuing phenotype; deletion early in life in the
Alb–Cre model is associated with the most marked oval cell
expansion and the highest proportion of mixed HCC/CC histology
in the liver tumours, whereas the tumours arising spontaneously in
Mst1
 / /Mst2
þ/  mice, which have little or no oval cell expansion
before the random allele loss, are overwhelmingly HCC. In
Drosophila, elimination of Yorkie is alone sufficient to revert the
Hippo and Salvador (Sav1) loss-of-function phenotypes. Consis-
tent with this, acute inactivation of Mst1/Mst2 in the liver is
associated with rapid loss of Yap(Ser127) phosphorylation,
increased Yap nuclear localisation and polypeptide abundance
(Zhou et al, 2009). Yap is regulated by the ubiquitin–proteosome
machinery via interaction with the E3-ligase b-TRCP, and it seems
that Yap(Ser381) phosphorylation promotes Yap degradation
(Zhao et al, 2010); the loss of this phosphorylation likely
contributes to the rise in Yap protein levels in the Mst1/Mst2
KO liver. The changes in Yap phosphorylation, localisation
and abundance seen after acute Mst1/2 inactivation are further
accentuated in the subsequent Mst1/2 null HCC’s and in cell lines
derived therefrom. Yap knockdown in these Mst1/2-deficient HCC
cell lines leads to massive cell death and cell cycle arrest; similarly,
restoration of Mst1 expression in these cells restores Yap (Ser127)
phosphorylation and engenders cell cycle arrest and apoptosis.
Hence, the Mst1/Mst2-dependent inactivation of Yap is a critical
tumour suppressor mechanism.
Two groups have described liver specific inactivation of Sav1/
WW45 (Le et al, 2010; Lu et al, 2010; Table 1). The Alb–Cre-
mediated excision of Sav1 results in a modest enlargement of the
liver, plateauing at B1.5-fold over wild type, as compared with the
four- to five-fold enlargement seen with Mst1/Mst2 double
knockout. The Sav1-deficient livers exhibit a marked expansion
of oval cells, however in contrast to the Mst1/Mst2-deficient livers,
the Sav1 null livers do not show a parallel overproliferation of
adult hepatocytes (Le et al, 2010). Liver tumours arose in Sav1
þ/ 
mice and more reliably in the Alb–Cre Sav1 lox/lox mice and
CAGGS–CreERT Sav1 lox/lox mice; nearly all of these were of a
mixed HCC/CC histology. Moreover, these tumours were usually
seen after 12 months age, considerably later than in the Mst1/Mst2
null livers. The liver of Alb–cre Sav1 null mice show a progressive
increase in Yap polypeptide greater than that seen in Mst1/Mst2
null livers, with highest levels present in the Sav1 null liver
Mst1/2signalling to Yap
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Yap(Ser127) phosphorylation persists, the nuclear abundance of
Yap is nevertheless also increased. The functional importance of
Yap to the hyperproliferative behaviour of Sav1 null oval cells,
although likely, remains to be demonstrated. It is notable that
despite the evidence that Yap is activated in oval cells harbouring
Hippo pathway defects, oval cell expansion in mice overexpressing
Yap in the liver has not been described (Dong et al, 2007).
This may reflect the relative activity in different cell lineages of the
promoter used to drive Yap expression in these studies. In this
regard, it is notable that the Yap transgenic mice show expansion
of undifferentiated progenitor cells in the intestine and other
tissues (Camargo et al, 2007). The changes in the Alb–cre Sav1
null livers seem to be attributable entirely to the oval cell
compartment; adeno–Cre infection of isolated Sav1ff oval cells
in vitro results in increased abundance and phosphorylation of
Yap and Lats1 as well as more Mst1 polypeptide, paralleling the
changes seen in the Alb–cre Sav1 null liver, whereas Sav1 deletion
from isolated hepatocytes gives little change in the abundance or
phosphorylation of these elements (Le et al, 2010). Overall the data
seem to point to a general role for Mst1/Mst2 in regulation of liver
cell proliferation, and a restricted function of Sav1 in oval cells
(Figures 1 and 2).
The co-occurrence of marked oval cell expansion and mixed
HCCs/CCs in the Sav1-deficient mice suggests the tumours arise
from transformed oval cells that retain some capacity for
hepatocytic and cholangiocytic differentiation. The broader
induction of cell proliferation associated with Mst1/Mst2 inactiva-
tion appears to indicate that multiple cell lineages may undergo
transformation in this context.
Table 1 Description of the different phenotypes resulting in the inactivation of the Sav1, Mst1/2, YAP and NF2/Mer genes in mouse
Gene  Mice  Liver defects    Liver tumourigenesis   Reference  
Sav1
Sav1
+/– Focal proliferation and
expansion of oval cells 
Mixed-type (HCC/CC)
tumours
by 12 months of age 
 
Lee et al (2010) 
Sav1
–/– Late embryonic lethality  Rare surviving mice develop 
liver tumours 
CAGGS-CreERT Sav1
c/c
MMTV-Cre Sav1
c/c 
 
All mice exhibit mixed liver 
tumours by 14 months of age  
Lu et al (2010)  
Albumin-Cre Sav1
c/c
Increased liver size 
Specific proliferation and
expansion of oval cells 
 
Liver tumours with a mixed 
(HCC/CC) phenotype at
13–14 months of age 
Lee et al (2010);
Lu et al (2010) 
Mst1,2 
Mst1
–/– None
Zhou et al (2009);
Oh et al (2009) 
Mst2
–/– None
Mst1
–/– ; Mst2
–/–
Mst1
–/– ; Mst2
+/–
Mst1
+/– ; Mst2
–/–
Embryonically lethal
(by E9.5) 
 
Liver overgrowth, oval cell 
expansion (associated with 
Mst2 LOH) 
HCCs with foci of CC by age
7months (6 out of 7 mice). 
 Lethal tumours by 15 months
(13 out of 16 mice) 
 
 
Zhou et al (2009),
and unpublished
data 
 
Occasional Mst1 LOH with 
liver overgrowth 
Lethal liver tumours (HCCs 
with foci of CC) by  15 
months (3 out of 12 mice) 
CAGGS-CreERT Mst1
–/– ; Mst2
c/–
Liver enlarged 1–7 months 
after gene inactivation 
Overproliferation of 
hepatocytes and oval cells  
Liver tumours develop by
age 6 months, mostly HCCs
with foci of CC 
 
 Song  et al (2010)
Ad-Cre Mst1
–/– ; Mst2
c/–
Liver overgrowth, evident 3 
days after gene inactivation 
Hepatocyte and oval cell 
proliferation 
Resistance to FAS-induced 
apoptosis 
Lethal livers tumours (HCCs 
with foci of CC) 10 weeks 
after injection 
Zhou et al (2009), 
and unpublished 
data 
Albumin-Cre Mst1
–/– ; Mst2
c/–
Liver enlargement at 1 
month of age, with increased
hepatocyte proliferation 
  Dysplasia at 1 month  Song et al (2010) 
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OF THE HIPPO PATHWAY IN LIVER
Surprisingly, in contrast to Drosophila, Zhou et al (2009) find that
Lats1/2 do not appear to serve as the direct, Mst1/Mst2-activated
Yap kinases in hepatocytes (Figure 2B). Whereas Yap phosphor-
ylation is markedly reduced by the acute elimination of Mst1/2
with adenoviral–cre, they find that phosphorylation of Lats1/Lats2
in liver is not significantly changed, nor is it altered by restoration
of Mst1 into Mst1/2 null HCC cells; in contrast Le et al (2010) find
Lats1/2 phosphorylation to be diminished in the Alb–cre/Mst1/
Mst2 double knockout liver. Chromatographic separation of liver
extracts and assay for Yap(Ser127) kinase demonstrates two peaks
of activity; acute inactivation of hepatic Mst1/2 selectively
eliminates one peak, whose elution is entirely distinct from that
of immunoreactive Lats1 and Lats2 (Zhou et al, 2009). These data
point to the existence of an novel, as yet unidentified intermediary
kinase downstream of Mst1/Mst2 that is critical for Yap(ser127)
phosphorylation in the liver; identification and elimination of this
putative novel Mst1/Mst2-regulated kinase will be required to
establish its physiologic role as a pathway component and liver
tumour suppressor.
The unanticipated finding that Sav1 inactivation in the liver
selectively affects the oval cell population, with little or no
impact on pathway components in hepatocytes (Le et al,
2010; Lu et al, 2010) indicates that the resultant oval cell
proliferation is a cell intrinsic response rather than a response to
a hepatocyte-generated damage signal; whether this is true of the
oval cell proliferation in the Mst1/Mst2 null liver is unresolved.
The Alb–cre mediated inactivation of a floxxed Neurofibroma-
tosis 2 (NF2) gene results in the massive expansion of a periportal,
CK2 positive cell population, variously called oval cells (Benha-
mouche et al, 2010) or biliary epithelial ‘hamartomas’ (Zhang et al,
2010); this results in gross liver enlargement with the subsequent
development of HCC, CC or tumours of mixed histology. The
selective oval cell expansion of the NF2-deficient mouse liver is
similar to, but more pronounced than that described for the Sav1-
deficient liver but differs from the expansion of both hepatocytes
and oval cells seen with Alb–cre-mediated Mst1/Mst2 double
knockout. The NF2 null liver phenotype is effectively suppressed
by treatment of the NF2-deficient mice with erlotinib (Benha-
mouche et al, 2010), an inhibitor of the EGFR (and other) kinases,
or by heterozygous inactivation of Yap1 (Zhang et al, 2010). The
Alb–cre-mediated biallelic inactivation of Yap1 in liver per se
Table 1 Continued
Albumin-Cre Mst1,2
c/c  
Albumin-Cre Mst1
–/– ; Mst2
c/c 
Increased liver size from 1 
month of age, due to 
hepatocyte proliferation 
 
Accumulation of oval cells at  
2 months of age 
HCCs begin to develop 
around 4 months of age 
Lu et al (2010)
Massive liver overgrowth by  
3 months of age 
Mixed-type (HCC/CC) tumours 
and HCCs by 3 months of age 
Zhou et al (2009),
and unpublished 
data 
YAP
Double transgenic  
LAP1/tTA-YAP S127A  Hepatocyte proliferation and  
increased liver size after  
activation of an inducible 
YAP transgene (reversible 
effect) 
Hepatocytes resistant to  
FAS-mediated apoptosis 
 
Camargo et al
(2007)  
Double transgenic  
ApoE/rtTA-YAP 
Lethal HCCs  Dong et al (2007)
Albumin-Cre YAP 
c/c 
Increased liver size 
Defects in hepatocyte 
survival  
 
Bile duct development 
severely impaired 
 
Zhang et al (2010)
Mer  
Nf2
+/– None 
High-grade HCC, with LOH at 
the Nf2 locus and high 
metastatic potential 
McClatchey et al
(1998)  
Albumin-Cre Nf2 
c/c
Extensive proliferation of 
biliary epithelium and 
hepatocytes  
 
Bile duct hamartomas and 
HCCs in 100% of the mice at 
1 year of age 
Zhang et al (2010)
Hepatomegaly due to a 
sustained overproliferation
of oval cells, leading to the
death of 70% of mice 
between 6 and 30 weeks. 
All surviving mice develop 
both CCs and metastatic 
HCCs within the same liver.
Mixed (HCC/CC) tumours are
also frequently observed. 
Benhamouche
et al (2010)
Abbreviations: CC¼cholangiocarcinoma; HCC¼hepatocellular carcinoma; LOH¼loss of heterozygosity. The principal defects and tumourigenic effects observed in the liver
are summarised for each genotype.
Mst1/2signalling to Yap
J Avruch et al
29
British Journal of Cancer (2011) 104(1), 24–32 & 2011 Cancer Research UKcauses a failure of bile duct development and hepatocyte apoptosis,
both in vivo and in ex vivo culture (Zhang et al, 2010). The
suppressive effect of Yap1 deletion on the overgrowth and
tumourigenesis of the NF2-deficient liver is specific, in that Yap1
deletion has no impact on tumourigenesis in KiRas mutant livers.
The evidence implicating NF2 in the negative regulation of yorkie
in Drosophila and Yap1 in cell culture is strong; whether NF2
downregulation of EGFR signalling is an independent, parallel
output of NF2 in oval cells or involves Yap1 as an intermediate is
not clear. Moreover NF2 deficiency in humans is not accompanied
by hepatic tumourigenesis, and the role of either pathway in the
tumours resulting from human NF2 deficiency, as compared to
NF2 inhibition of the CRL4
DCAF1 ubiquitin ligase (Li et al, 2010) is
an open question.
MECHANISMS OF Mst1/Mst2 REGULATION IN THE
LIVER
Three mechanisms for the physiologic activation of endogenous
Mst1/2 are described thusfar, each involving phosphorylation
within the activation loop (Praskova et al, 2004). In the canonical
Hippo pathway, Sav1 is needed not only to facilitate Lats1/2
activation by Mst1/2, but also to enable Mst1/2 activation. Thus in
Sav1 null keratinocytes, the ability of extracellular Ca
þþ to
activate Mst1/2 activation loop phosphorylation is markedly
impaired (Lee et al, 2008). The biochemical mechanism by which
Sav1 mediates Mst1 activation is unclear; Mst1/2/Hippo associate
with Sav1/salvador through their mutual SARAH domains, but this
alone is not sufficient to cause activation.
A second mechanism for Mst1/2 activation is through their
association with the Rassf family of polypeptides (Avruch et al,
2009). The major expressed isoforms of Rassf (1–6) all contain at
their carboxyterminus a canonical ras–rap association (RA)
domain followed by a SARAH domain. The RA domain enables
binding to the GTP-charged forms of several Ras family GTPases,
whereas Mst1/2 is capable of heterodimerisation with all such
Rassf polypeptides through their mutual SARAH domains
(Khokhlatchev et al, 2002). The affinity of the Rassf5/Nore1SARAH
domain for the Mst1 SARAH domain greatly exceeds that of
either homodimer (Hwang et al, 2007), and constitutive Rassf5/
Mst1 and Rassf1/Mst1 heterodimers are evident in cells and
tissues (Praskova et al, 2004). Although the Sav1 and Rassf5/Nore1
SARAH domains seems to interact with different surfaces on the
Mst1 SARAH domain (Hwang et al, 2007), there is conflicting data
as to whether endogenous heterotrimers occur (Polesello et al,
2006; Guo et al, 2007); therefore, whether Sav1 and Rassf mediate
entirely independent pathways that each contain Mst1/2 or
pathways that physically converge at Mst1/2 is currently un-
resolved. Mst1/2 regulation by Rassf polypeptides has been best
studied in the murine T cell (Katagiri et al, 2006; Zhou et al, 2008).
In resting cells, Mst1 in complex with Rassf5b/Nore1b is inactive,
however, activation of chemokine or antigen receptors results in
recruitment of the heterodimer to Rap1–GTP at the membrane and
activation of Mst1 through a mechanism yet to be defined. Little
information is available concerning regulation of other Rassf/
Mst1-2 complexes and in other tissues.
Mst1 and Mst2 also become activated in cells undergoing
apoptosis from a variety of stimuli. The activation mechanism is
unclear however once activated, both kinases undergo cleavage by
caspase3 at sites just carboxyterminal to their catalytic domains
(Graves et al, 1998). The resultant catalytic polypeptides display an
altered substrate specificity (Anand et al, 2008); moreover now
lacking their autoinhibitory domain, the caspase-cleaved catalytic
fragments are highly and constitutively active with unrestricted
nuclear access (Ura et al, 2001).
A striking feature of Mst1/2 regulation in liver is the finding that
a substantial fraction of Mst1 and some Mst2 are present as
constitutively active, presumably caspase-cleaved catalytic frag-
ments (Zhou et al, 2009). This contrasts with unstimulated T cells
and MEFs, wherein Mst1/2 are found exclusively as the full length
polypeptides, inactive unless the cells are stimulated or subjected
to proapoptotic treatments. Notably however, in these cells the
outputs of Mst1/2 as well as their regulation differs from that in
hepatocytes. In T cells, Mst1 activation by the T-cell receptor
promotes integrin clustering independently of Yap (Katagiri et al,
2006; Zhou et al, 2008). In MEFs, cell–cell contact activates Lats1/2
and promotes Yap(Ser127) phosphorylation equally well in wild-
type and Mst1/2-deficient cells (Zhou et al, 2009). Thus the basal
activity of Mst1 (especially) and Mst2 in liver seems to be uniquely
high and tightly coupled to Yap inhibition, a situation that is
probably of major importance to the maintenance of hepatocyte
proliferative quiescence. Although further work is needed to verify
the role of caspase3 in the generation of these Mst1/2 fragments, a
non-apoptotic role for caspase3 in the suppression of cell
proliferation and promotion of differentiation has been previously
demonstrated in embryonic and hematopoietic stem cells (Fujita
et al, 2008; Janzen et al, 2008) and in myoblasts (Fernando et al,
2002), in the latter involving Mst1 cleavage.
The mechanism underlying the activation of hepatocyte Mst1
activation before its caspase cleavage is not yet known. The finding
that Alb–cre-mediated Sav1 deletion has a selective effect on oval
cell proliferation points to a role for Sav1 in Mst1/2 regulation in that
compartment, but implies as well that other mechanisms of Mst1/2
activation may be predominant in the hepatocytes. Although
epigenetic inactivation of Rassf1A and of Rassf5b/Nore1b has been
reported in HCC (Calvisi et al, 2006; Macheiner et al, 2006), whether
hepatocyte Mst1/2 activation involves Rassf(1-6) polypeptides, or as
yet unidentified mechanisms is not known.
ROLE OF Mst1/2-YAP PATHWAY IN HUMAN LIVER
CANCERS
The contributions of the core Hippo pathway components to
human malignancies has received limited attention thus far.
Mutations in Mst1/2, Lats1/2 and Sav1 in human cancers are very
infrequent in the COSMIC catalogue, however there is evidence of
promoter silencing by hypermethylation in some cancer types
(e.g., Lats1/2 in breast cancers; Takahashi et al, 2005). As to liver
cancer, the most compelling information relates to Yap. Approxi-
mately 50% of human HCC’s show aberrant overexpression and
nuclear localisation of Yap (Dong et al, 2007; Zhao et al, 2007), a
small fraction of which is attributable to Yap gene amplification
(Zender et al, 2006). Cell lines derived from human CC exhibit
extensive apoptosis consequent to shRNA-induced deficiency of
Yap, and the murine and human liver tumours of mixed HCC/CC
morphology exhibit substantially increased nuclear abundance of
Yap (Zhou et al, unpublished observations). Thus, Yap is probably
a significant oncogene is all subtypes of liver cancer.
As regards the mechanisms underlying aberrant Yap activation,
our preliminary immunoblot analysis of lysates from human HCC
and adjacent non-neoplastic liver (Zhou et al, 2009) show that
B30% of tumours have reduced Yap(Ser127) phosphorylation,
while retaining wild-type or upregulated Yap protein levels.
Moreover, the cleaved, activated Mst1/Mst2 peptides are absent
in a similar proportion of HCCs and the extent of pMob(Thr12)
phosphorylation, a highly specific substrate of Mst1/2 (Praskova
et al, 2008; Zhou et al, 2008, 2009), is greatly reduced. These
findings point to a deficiency in the upstream activating input to
Mst1/2 in HCC, and emphasise the importance of defining this
regulation. Thus, loss of regulation upstream of Mst1/2 is a
common abnormality in human HCC and may account for Yap
activation in these tumours. It is not yet clear whether Yap
dysregulation is a feature of the hyperproliferative states that
precede HCC or is a late consequence of transformation.
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Mst1/2, Yap, and Sav1 are now clearly established as regulators of
liver cancer pathogenesis, yet many questions remain. Of primary
importance is the need to understand the mechanisms that
underlie Mst1/2 activation in hepatocytes and oval cells, that is,
the nature of the activating signals and the role of cell surface
proteins such as the atypical cadherin Fat and sub-membrane
FERM domain scaffold proteins, such as Merlin/NF2 and
Expanded, elements known to be functionally associated with the
Drosophila Hippo pathway (reviewed by Reddy and Irvine, 2008).
It will be important to examine whether Mst1/2 cleavage in liver is
a passive consequence of Mst1/2 activation or is itself regulated.
Is Mst1/2 cleavage required for liver quiescence and does such
cleavage also occur in the wild-type oval cells as well as in
hepatocytes; how does cleavage influence Mst1/Mst2 subcellular
localisation and target specificity. The identification of the novel
Mst1/2 activated kinase that phosphorylates and inhibits Yap1 in
liver is of great interest as are the mechanisms by which Sav1
controls Yap1 levels in oval cells. The contribution of Yap and
other factors to oval cell overproliferation remains to be formally
determined. A more comprehensive elucidation of the transcrip-
tion factors and transcriptional outputs downstream of Yap in liver
is needed. It is important to note that, although Yap is clearly the
oncogene that is negatively regulated downstream of Mst1/2 in
liver, Yap also has antiproliferative, propapototic outputs in other
cellular milieus, presumably reflecting its context-dependent
interactions with transcriptional regulators unrelated to those
that define Yap function in the Hippo tumour suppressor pathway
(e.g., p73; Matallanas et al, 2007; Oh and Irvine, 2010).
In terms of human liver cancers, it will be important to identify
clinically useful biomarkers for deregulation of Mst1/2 signalling in
human HCC and CHC. At present, Yap IHC staining of liver biopsy
is commonly used (Steinhardt et al, 2008). Additional antibody
against phospho-Mob1 used for IHC staining needs to be developed.
Other important issues are to define the clinical correlates of liver
cancers that show deficient Mst1/2-Yap regulation (Xu et al, 2009),
and to determine whether there are druggable targets in this
pathway, for example, upstream of Mst1/2 or downstream of Yap1.
Enhancement of Mst1/2 kinase activation or inhibition of Yap
expression or function may prove a valuable strategy for drug
design and discovery to improve therapy for HCC patients.
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